IgE-associated allergy is the most common and important immunologically mediated hypersensitivity disease affecting approximately 30% of the population worldwide.[@R1],[@R2] In the USA, allergies are a leading cause of chronic illness representing an immense burden for the health care system.[@R3] The identification of the disease-causing allergens is critical for the accurate diagnosis of allergy and forms the basis for the treatment of allergic patients by allergen-specific interventions (eg, allergen avoidance, diet, allergen-specific immunotherapy \[AIT\]).[@R4] AIT is in fact the only causal, disease-modifying, and long-lasting form of treatment.[@R4],[@R5] Therefore considerable efforts have been spent in the characterization of allergens beginning with the isolation of allergens from the natural allergen sources by biochemical means.[@R2],[@R6],[@R7] A major breakthrough regarding allergen characterization has been achieved with the introduction of molecular cloning techniques for the isolation of the genes coding for allergens.[@R8] Thirty years ago the genes coding for the first allergens were isolated and sequenced, and soon thereafter the first recombinant allergens were produced and used for *in vitro* diagnosis of allergy.[@R9]--[@R11] In 1999, recombinant allergens were made available in a fully automated *in vitro* allergy diagnostic test system,[@R12] and the first allergen chip containing micro-arrayed allergen molecules to be used as a multiallergen test was reported in 2002.[@R13] Since then, *in vitro* allergy diagnosis has been revolutionized by molecular allergy diagnosis.[@R6],[@R14] However, recombinant allergen molecules have also been used for *in vivo* allergy diagnosis. More than 20 years ago the first skin prick test studies and also *in vivo* provocation test studies (eg, bronchial provocation, nasal provocation) were performed with recombinant allergens in patients and showed that recombinant allergens can be effective, safe, sensitive, and specific when used for *in vivo* allergy diagnosis.[@R15]--[@R22] Despite the fact that several clinical studies have documented the advantages of recombinant allergen--based skin testing over allergen extract---based skin testing regarding specificity and clinical information,[@R18],[@R19],[@R21],[@R23] up to now no recombinant allergen---based *in vivo* tests are available. Presently only allergen extract---based tests that are not complying with the regulations for medicinal products are available for *in vivo* allergy diagnosis (ie, mainly skin testing). In fact, double-blind, placebo-controlled studies comparing sensitivity and specificity of the *in vivo* test allergen in patients for whom IgE reactivity profiles have been determined in parallel by serology would be desirable.

Likewise, recombinant allergen derivatives and recombinant allergens have been successfully evaluated for AIT more than 10 years ago.[@R24]--[@R26] Unfortunately, only few molecular AIT approaches have been moved successfully into clinical evaluation,[@R24]--[@R31] and there are therefore currently only allergen extract---based allergy vaccines available.

However, also only for few of the allergen extract---based AITs safety and efficacy have been documented according to the current rules for medicinal products as demanded by the European Directive 2001/83/EC in 2004.[@R32] For most of the AIT products, no sufficient documentation in the form of properly randomized, double-blind, placebo-controlled clinical trials is available. We found only 2 subcutaneous immunotherapy (SCIT) products for grass pollen allergy,[@R33],[@R34] 2 sublingual immunotherapy (SLIT) products for grass pollen allergy,[@R35]--[@R37] 1 SLIT product for ragweed pollen allergy,[@R38] and 2 SLIT products for house dust mite allergy,[@R39]--[@R43] which have been evaluated in large numbers of patients. Several large-scale clinical trials with allergen extracts are currently registered in the clinical trial database (<https://clinicaltrials.gov/>), but results are not yet published and it seems that a longer transition period is needed to implement European Directive 2001/83/EC. Regarding allergen extracts for *in vivo* diagnostic testing so far no studies and/or documentation satisfying the demands of European Directive 2001/83/EC are available and there are discussions ongoing if there should be a distinction between therapeutic and diagnostic allergen preparations.

In the next section, we discuss the problems that are associated with the preparation and characterization of allergen extracts from natural allergen sources to meet current requirements for medicinal products. Although allergen extracts to be used for *in vivo* allergy diagnosis and AIT need to be distinguished, they fall under the definition of medicinal products (ie, "any substance or combination of substances that may be used in or administered to human beings either with a view to restoring, correcting, or modifying physiological functions by exerting a pharmacological, immunological, or metabolic action, or to making a medical diagnosis").

Allergen Extracts: Production and Quality Control {#S1}
=================================================

For a long time expert opinion was sufficient to place allergen products for *in vivo* diagnosis and therapy on the market and clinical studies following good clinical practice (GCP) standards were never performed. In many countries, especially in the European Union, the legal situation has dramatically changed during the last 2 decades. It is now required to demonstrate safety and efficacy for therapeutic allergen products as well as for allergen products used for *in vivo* application such as diagnostic allergen extracts used for provocation testing, including skin testing, bronchial, nasal, conjunctival, and food provocation testing.[@R44],[@R45] Although there are differences regarding the regulations in different continents and countries,[@R44]--[@R49] the overall goal is that according to the "International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use" ([http://www.ich.org/home.html](https://www.ich.org/home.html)), medicinal products that include also allergen products for *in vivo* diagnosis and treatment must be evaluated in clinical trials and undergo a thorough evaluation to be registered for use in patients. A major prerequisite for clinical trials and subsequent use in humans is that the medicinal product is produced following good manufacturing practice (GMP) and is shown to have consistent characteristics and quality. This requirement is already a major hurdle for allergen extracts that are produced from natural allergen sources. [Figure 1](#F1){ref-type="fig"} provides an overview of the steps leading to a diagnostic or therapeutic allergen extract. A first major problem relies in the allergen source that is used for the production of allergen extracts. The contents, concentrations, and ratios of the individual allergens have been reported to vary greatly depending on a large variety of factors.[@R50]--[@R55] Only a few examples shall be mentioned in this context: for example, allergen contents in pollen vary depending on environmental factors such as ozone exposure,[@R56] pollution,[@R57] and plant species to name a few.[@R58] The contents of house dust mite allergens and their ratios depend on the growth conditions of mites, how they are fed and cultivated, and what mite material (feces, bodies) is used as raw material for the production of extracts.[@R59] In the case of animal allergens, allergen type and contents may vary depending on gender.[@R60],[@R61] Food allergens are expressed to a different extent in different parts of fruits and cultivars,[@R62] and are extracted differently depending on the method used for extraction.[@R63] Lipophilic allergens have therefore been overlooked for a long time.[@R64],[@R65] The spectrum of mold allergens shows great variation depending on mold strains and culture conditions.[@R55] Furthermore, it has been shown that allergens occur in pollen as different isoforms with different allergenic activities and immunological properties in varying quantities, which means that no homogeneous single natural allergen preparation can be obtained from a natural allergen source.[@R66]--[@R68] Therefore, only the recombinant expression of a defined isoform based on the corresponding gene can overcome this problem.

The presence of proteases in allergen extracts is another major problem because it may lead to the degradation of allergens that affects the allergenic activity, immunogenicity, and immunomodulatory capacity of an allergen extract.[@R69]--[@R74] Because protease inhibitors that can help overcoming this problem are often toxic, it is impossible to prevent allergen degradation in extracts by the addition of such protease inhibitors. Certain allergens are proteases by themselves and therefore can digest not only other allergens but also may have effects on immune cells and tissues in the allergic patient on administration. This was shown for example for fungal allergens in mouse models but also for the major house dust mite allergen *ex vivo* for the human system.[@R71]--[@R74]

Some allergens are toxic and, at high concentrations, may induce inflammatory reactions *per se* in a nonsensitized subject.[@R75]

Another major problem is that allergen extracts contain a large variety of unknown nonallergenic materials that may have toxic and/or immunomodulatory effects. For example, it has been shown that nonallergenic components such as pollen-derived phytoprostanes may activate cells of the innate immune system (ie, dendritic cells) "unspecifically" and thus indirectly have effects on the adaptive immune response by inducing Th2 responses. Such effects have been observed for pollen and house dust mite allergen extracts.[@R76],[@R77] Another major concern is that allergen extracts may contain contaminants from other allergen sources. For example, the presence of house mite allergens in animal dander allergen extracts has been reported,[@R78] pollen may be contaminated with unrelated pollen or fungi, and recently the presence of IgE-reactive bacterial antigens in house mite allergen extracts has been reported.[@R79]

When allergen extracts are prepared from natural allergen sources, one must therefore analyze not only the presence of intact allergens but also of allergen-derived materials exhibiting different properties as the intact allergens (eg, allergen peptides) ([Figure 1](#F1){ref-type="fig"}). In this context, it should be mentioned that fractions of allergen extracts with different molecular weights have been shown to exhibit different allergenic and immunomodulatory properties as has, for example, been shown already early for grass pollen extracts.[@R80] Furthermore, the presence of nonallergenic materials and possible contaminants requires analysis ([Figure 1](#F1){ref-type="fig"}).

The analysis of the different materials in an extract (ie, allergen, allergen-derived materials, nonallergenic materials, contaminants) ([Figure 1](#F1){ref-type="fig"}) must include many different parameters such as contents, concentrations, quality, ratios, activity parameters (eg, allergenic activity, immunogenicity, immunomodulatory activity), shelf-life, and stability; chemical and biological properties related to safety must be characterized for each of the different components, which is an extremely complex process. There are methods that in principle allow us to analyze the aforementioned parameters for single molecules with sufficient accuracy. Mass spectrometry has recently been proposed as a method for the standardization of allergen extracts.[@R81] However, mass spectrometry can only demonstrate the presence of certain allergen-derived peptides in an extract but is not a real quantitative method and cannot tell anything about the allergenic or immunogenic properties of the molecules.[@R82] Unfortunately, there is therefore no method that can analyze all important characteristics (physicochemical, structural, immunological properties) of the individual components present in complex mixtures such as allergen extracts at the same time.

The allergen extraction process is not a real purification process of certain allergen molecules but leads to a crude bulk allergen extract that can be further used for different purposes ([Figure 1](#F1){ref-type="fig"}). Allergen extracts for *in vivo* diagnostic testing are usually prepared from the bulk allergen extracts by dilution and addition of certain preservatives. In this context, it has been found that certain allergen extracts contain also components that have been added during the manufacturing process. For example, human serum albumin is sometimes added by the manufacturers for stabilization purposes.[@R50],[@R51],[@R54] Mixed allergen extracts are produced by mixing bulk allergen extracts from different allergen sources that may create several problems. For example, mixing of allergens dilutes the concentrations of allergens from each of the extracts that has been used for mixing to an unknown extent or may introduce proteases from other allergen sources leading to degradation.[@R83]--[@R86] Denaturation of allergen extracts by various physicochemical procedures is performed for allergen extracts used for AIT to reduce the allergenic activity. There are different processes for denaturation such as aldehyde treatment, boiling, chemical denaturation, and various other treatments, but these procedures cannot be fully controlled and therefore affect to various degrees allergenic, immunogenic, and immunomodulatory properties of allergen extracts.[@R87],[@R88] Importantly, individual allergens cannot be traced any more as intact molecules in chemically modified or denatured allergen extracts, and one therefore can only try to assess the overall allergenic and/or immunogenic activity of a denatured extract, both of which may vary from one production batch to another.[@R49],[@R89]

Finally, one has to consider that allergen extracts to be used for AIT are manufactured in different ways. Some allergen extracts are made as aqueous solutions without adjuvants, some are mixed with powders and excipients to form tablets, and some extracts are adsorbed to different adjuvants to which individual allergens may bind with different strength and stability.[@R90]--[@R93] All these additional processes may affect individual allergens/immunogens to a different extent and thus introduce another layer of uncertainty in addition to those due to variations caused by allergen sources and methods of extraction, processing, denaturation, and mixing.

Methods for the Quality Control of Allergen Extracts {#S2}
====================================================

In [Table I](#T1){ref-type="table"} we have summarized advantages and disadvantages of different methods that can be used for the quality control of allergen extracts. For example, the determination of the total protein contents has been introduced as one of the first methods for the quality control of allergen extracts.[@R94] It measures protein contents but does not identify specifically allergens and their properties. Methods for measuring the allergenic activity and IgE reactivity of allergen extracts (ie, potency assays) were introduced later as additional methods for quality control.[@R95] These methods depend on reagents derived from patients because allergen extracts are assessed for reactivity with IgE antibodies, in basophil activation tests or by skin testing.[@R95],[@R96] Since allergic patients react with different allergens and have different sensitivities to these allergens, results obtained with potency assays depending on patients materials will vary widely. As a result, allergen preparations that are standardized according to such methods in different countries cannot be compared.[@R48] Potency assays measuring the allergenic activity cannot be used for allergen extracts that have been modified to reduce allergenic activity, except one wants to measure the extent of reduction of allergenic activity in comparison with an unmodified allergen extract.

In addition, a series of biochemical and biophysical methods have been developed. They include, for example, mass spectrometry, circular dichroism, size exclusion that allows the detection of allergen peptides, and the analysis of the fold of proteins and of the aggregation behavior, respectively.[@R97],[@R98] In particular, mass spectrometry has been suggested as a powerful method for the standardization of allergen extracts.[@R81],[@R99],[@R100] Although circular dichroism and gel filtration are very useful and suitable for the analysis of single purified molecules,[@R101] these methods cannot be used for complex allergen mixtures. Sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting allow the qualitative analysis of allergen extracts and may discriminate between intact allergens, aggregation, and degradation products according to molecular weight.[@R102] Quantitative enzyme-linked immunosorbent assays performed with allergen-specific antibody probes permit the determination of the concentrations of intact allergens.[@R103]--[@R105] The determination of the ability of an allergen extract to induce the production of allergen-specific IgG antibodies that block patients' IgE binding can be obtained by immunization of animals with the formulated vaccine.[@R106] Because antibodies induced in inbred mouse strains by allergy vaccines recognize other epitopes than those induced in allergic patients, it is recommended to perform immunization experiments in outbred animals such as rabbits.[@R89] The IgG antibodies obtained in the animals can then be tested for their ability to inhibit allergic patients' IgE binding to the allergens and allergen-induced effector cell activation. In fact, a recent study showing that cat allergy can be treated by passive immunization with recombinant allergenespecific antibodies emphasizes the importance of blocking antibodies for success of treatment and the need to test allergy vaccines for the induction of blocking antibodies in model systems.[@R107] However, clinical studies in humans and postmarketing assessment will always be required to assess the immunogenic properties of AIT vaccines because there may be differences of immunogenicity in animals and man.

In addition to the assays characterizing allergens, allergen-derived materials, nonallergenic components and contaminants, additional tests are mandatory for safety, stability, toxicity, and sterility assessment. These methods are mandatory for the quality control of medicinal products ([Table I](#T1){ref-type="table"}).[@R108],[@R109]

Allergen Extracts for Diagnosis and Treatment {#S3}
=============================================

[Table E1](#T4){ref-type="table"} (available in this article's Online Repository at [www.jaci-inpractice.org](https://www.jaci-inpractice.org/)) contains an overview of allergen extracts that we found to be registered or to be available in different continents and countries and, when available, the corresponding homepages of the regulatory agencies providing the information. As examples, we have analyzed a few countries, that is, the USA, Germany, Russia as well as Taiwan and Japan from Asia. However, already in this small selection of countries the heterogeneity of the regulations in different parts of the world becomes very clear.[@R110] However, one common feature seems to be that allergens, regardless of whether they are used for therapy or as *in vivo* test allergens, are considered as biological medicinal products and therefore require marketing authorizations that are usually issued for the finished product. In the USA, so-called standardized and also nonstandardized injectable allergen extracts from a variety of manufacturers are available ([Table E1](#T4){ref-type="table"}). However, we were unable to find published state-of-the-art clinical studies that document the safety, specificity, and efficacy for the majority of these products. Randomized, double-blind, placebo-controlled clinical studies following the rules set for medicinal products have only been performed for few extracts available as tablets for sublingual therapy.[@R35]--[@R43] The situation was similar for Germany. On the homepage of the Paul Ehrlich Institute that is responsible for the registration of medicinal products in Germany, extracts from several companies for skin testing and provocation testing are listed, but for none of these test allergen extracts we could find any documentation by clinical studies. For a handful of allergen extracts available for subcutaneous and sublingual AIT,[@R33]--[@R43] clinical studies have been performed, whereas for the majority of therapeutic products, no evidence for efficacy and safety in the form of clinical studies could be found. In fact, in the European Union (EU), allergen products such as AIT vaccines and allergen products used for *in vivo* testing are defined as medicinal products according to Directive 2001/83/EC and are therefore required to obtain a market authorization that can follow different procedures in individual EU countries or via a centralized procedure that is valid for the whole EU.[@R110] The current state-of-the-art approach for obtaining marketing authorization requires randomized, double-blind, placebo-controlled studies that are performed according to GCP guidelines, but in reality this has been fulfilled only for few AIT vaccines in the EU.[@R33]--[@R43] A similar situation was found for Russia, Taiwan, and Japan where a quite limited number of allergen extracts are available ([Table E1](#T4){ref-type="table"}). One possibility for making allergen extracts available without fulfilling new rules for allergen products is based on so-called named patient products that can be prescribed by practitioners on an individual patient basis.[@R32] However, it must be clear that the level of evidence for such products is very low (ie, expert opinion) and named patient prescription hence does not follow the current rules for medicinal products.

The legal situation in the USA is that allergen products are regulated as biological medicinal products under the Public Health Service Act and as drug product under the Federal Food, Drug and Cosmetics Act, and require a marketing authorization termed a biologics license application (BLA). The BLA has to demonstrate that the product is manufactured under GMP and is safe, pure, and effective. Thus randomized, double-blind, placebo-controlled studies according to the current GCP regulation are now required for marketing authorization. In the EU, the pharmaceutical industry has been requested to provide the necessary documentation for their products, and accordingly clinical studies are currently performed, however, mainly for AIT products but not for allergen extracts used for *in vivo* testing. It is therefore not surprising that there is a great risk that many natural allergen extracts will disappear in the EU, especially those for *in vivo* testing.[@R44] Ultimately, also many AIT extracts may not be available any more in the future. Although the regulatory situation is different in other countries, it cannot be excluded that the pressure on quality control on allergen extracts will increase suddenly also there because the continuously rising costs for health care systems will demand that the safety and efficacy of medicinal products and drugs is documented by extensive clinical studies. It will therefore be necessary to intensify the discussions between major allergy societies and international control agencies to provide reliable, safe, efficient, and cost-effective options for therapy and *in vivo* diagnosis and eventually to distinguish between therapeutic and diagnostic allergen preparations.

Transition from Allergen Extracts to Molecules: The Only Solution? {#S4}
==================================================================

If indeed the requirements for quality control and the documentation of safety and efficacy by clinical trials set by regulatory authorities increase for test and treatment allergens, there are basically at least 2 options. One option would be to fulfill the requirements with allergen extractebased technologies, whereas the other option would be to replace allergen extracts by defined recombinant allergen molecules and combinations of the 2 options can be envisaged. In [Table II](#T2){ref-type="table"}, we have performed a SWOT (Strength, Weakness, Opportunity, and Threat) analysis of the advantages and disadvantages of natural allergen extracts versus recombinant allergen molecules. One may argue that allergen extracts are traditional products that are known to the allergologist for a long time without requiring detailed knowledge regarding the individual allergen molecules. However, in the field of *in vitro* allergy diagnosis, molecular testing has become an important part of the diagnostic armamentarium of the allergologist, and it is argued that molecular testing will eventually completely replace extract-based testing.[@R6],[@R111],[@R112] Of course, molecular testing requires detailed knowledge of the individual allergen molecules and hence continued medical education to enjoy the many advantages of molecular testing (eg, understanding of cross-reactivities, precise identification of the culprit allergen, resolution of complex cases, refinement of AIT prescription, identification of sensitization to high- or low-risk allergens) over allergen extractebased testing.[@R7] One particular strength of molecular allergy diagnosis is that it allows us to identify precisely the culprit allergen sources in polysensitized patients that facilitate the accurate prescription of AIT.[@R6],[@R112] One may also consider the use of recombinant allergen mixes instead of natural allergen extracts. It is also possible that the knowledge gained from molecular allergen characterization may help to improve the quality of natural allergen extracts. The disadvantages of allergen extracts are mainly related to the fact that it is technically almost impossible to manufacture them in a way to satisfy the current requirements for medicinal products due to the limitations set by raw materials, extraction, and processing ([Table I](#T1){ref-type="table"}).

Recombinant allergens that exactly resemble the allergenic activity of the natural allergens as well as recombinant allergen derivatives with favorable properties for AIT are available now for decades and can be produced by controlled expression in appropriate host cells (eg, bacteria, eukaryotic cells) under defined conditions of GMP, which is the standard for medicinal products. Of course, the production of recombinant allergens and allergen derivatives requires a different know-how as compared with allergen extracts, but it is completely independent from natural and thus variable raw materials.[@R7] Because recombinant allergenebased products are new kids on the block, they will require clinical studies and market authorizations, but ultimately such studies also need to be performed for allergen extracts; otherwise they may disappear.[@R44] As a concrete example for the replacement of allergen extracts by recombinant allergenebased technologies, we would like to refer to grass pollen that is one of the most important allergen sources worldwide. It has been demonstrated that natural grass pollen allergen extracts show large variations regarding the contents of the individual allergens and therefore are highly heterogeneous.[@R50] Likewise, grass pollen extractespecific AIT induces only partial protective immune responses against the individual major allergens.[@R113],[@R114] All these problems could be overcome with a recombinant hybrid allergen comprising the 4 major timothy grass pollen allergens: Phl p 1, Phl p 2, Phl p 5, and Phl p 6.[@R115] This hybrid molecule can be easily produced in *Escherichia coli* in defined, reproducible quality and in a very large amount. The hybrid resembles the allergenic activity of grass pollen and can be used for *in vivo* diagnosis of grass pollen allergy.[@R116] The single recombinant hybrid molecule could also be used to formulate AIT vaccines for grass pollen because AIT with Phl p 1, Phl p 2, Phl p 5, and Phl p 6 has been shown to be clinically effective.[@R25] Moreover, several AIT approaches based on recombinant hypoallergenic molecules, recombinant allergens, and allergen-derived synthetic peptides have reached clinical application in controlled studies ([Table III](#T3){ref-type="table"}). One of these approaches is that a new recombinant B-cell epitope-based grass pollen allergy vaccine, termed BM[@R32],[@R30],[@R31],[@R130],[@R131] which contains recombinant hypoallergenic fusion proteins consisting of nonallergen peptides from the 4 timothy grass pollen allergens fused to the hepatitis B-derived PreS protein as a carrier, has been shown to be hypoallergenic *in vivo*.[@R132] In AIT trials, BM32 was safe and few injections were effective in reducing symptoms of grass pollen allergy ([Table III](#T3){ref-type="table"}).[@R30],[@R31],[@R133],[@R134] Thus grass pollen allergy is a very good and concrete example of how traditional allergen extracts used for *in vivo* testing and AIT can be replaced by modern recombinant technology.

Interestingly, recombinant allergenebased approaches seem to be not only applicable for the development of AIT approaches for respiratory allergies, but also for food and venom allergy. Regarding food allergy, a recombinant hypoallergenic mutant of the major fish allergen parvalbumin, mCyp c 1, has been expressed in *E. coli* and was shown to have strongly reduced allergenic activity in skin prick tests.[@R109],[@R135],[@R136] The recombinant mCyp c 1 molecule was then formulated for subcutaneous AIT, and first clinical studies showed that treatment was safe and induced allergen-specific blocking IgG antibodies ([ClinicalTrials.gov](https://clinicaltrials.gov/) Identifiers: NCT02017626, NCT02365168, NCT02382718). Likewise, recombinant allergenebased strategies might be developed for venom allergy because the clinically relevant bee and wasp allergens have been expressed as recombinant proteins and could be used to develop recombinant AIT approaches.[@R137],[@R138]

Summary {#S5}
=======

Recombinant hypoallergenic allergen derivatives comprising some of the most important allergen sources (eg, grass pollen, birch pollen, ragweed pollen, olive pollen, Parietaria pollen, cedar pollen, house dust mites, cat, dog, bee, and wasp venoms) have been characterized at a preclinical level and could be evaluated in clinical trials.[@R130],[@R131],[@R139]--[@R155] For a few allergen sources, it may be challenging to prepare all the individual allergen molecules by recombinant technology to represent the complexity of the allergen source properly. However, so far recombinant AIT approaches have not reached wide-scale use in clinical practice. Because the molecules can be produced well in different expression systems, there are, in principle, no technical hurdles for their manufacturing. Some of the molecules are protected by international patents, but these are available for licensing. It rather seems that pharmaceutical companies were so far not willing to invest in their development because this would require the setting up of suitable production facilities and the conductance of clinical trials. With the implementation of regulations requesting the documentation of traditional allergen extracts by clinical trials during the last few years, the situation may change because the pharmaceutical industry is now requested to conduct GMP production and clinical trials to maintain their traditional allergen extracts on the market and/or may decide to develop recombinant allergenebased products. It is therefore likely that the pressure by the regulatory agencies will boost the development of high-quality allergens for *in vivo* use, and, accordingly, we may see the parallel development of allergen extract and recombinant allergenebased products for clinical use. Unfortunately, most of the current allergen extracts do not meet the criteria of medicinal products and are therefore at risk of disappearing. Even with the most advanced analytical methods, it is not possible to overcome all the quality problems that are due to the limits of allergen extractebased technologies. However, during the last 30 years, the most important allergen molecules from the most relevant allergen sources have been produced as defined recombinant molecules resembling the allergenic activity of the natural allergens. The recombinant allergen molecules can be produced at low costs, in consistent quality, and in large amounts for *in vivo* allergy testing and thus would meet easily the criteria set for medicinal products. Likewise, they could be used to formulate modern allergy vaccines. Moreover, recombinant hypoallergenic allergen derivatives have been produced for most of the important allergen sources and hold promise to improve safety, efficacy, and convenience of allergen-specific immunotherapy as well as to be useful for preventive allergy vaccination. It is thus argued that the time has come to implement recombinant technology for the production of new high-quality *in vivo* allergy tests and allergy vaccines.

Online Repository {#S6}
=================

Extended Data {#S7}
-------------

###### 

Diagnostic and therapeutic allergen extracts registered in the USA, Germany, Russia, and Asia

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [**USA**]{.ul} (<https://www.fda.gov/BiologicsBloodVaccines/Allergenics/default.htm>)
     *Injectable allergen extracts standardized* (<https://www.fda.gov/BiologicsBloodVaccines/Allergenics/ucm391514.htm>)
         Cat Hair (*Felis domesticus*): 7 manufacturers
         Cat Pelt (*Felis domesticus*): 2 manufacturers
         Mite D.f. (*Dermatophagoides farinae*): 6 manufacturers
         Mite D.p. (*Dermatophagoides pteronyssinus*): 6 manufacturers
         Bermuda Grass (*Cynodon dactylon*): 6 manufacturers
         Kentucky (June) Bluegrass (*Poa pratensis*): 6 manufacturers
         Orchard Grass (*Dactylis glomerata*): 6 manufacturers
         Redtop Grass (*Agrostis alba*): 6 manufacturers
         Perennial Ryegrass (*Lolium perenne*): 6 manufacturers
         Sweet Vernal Grass (*Anthoxanthum odoratum*): 6 manufacturers
         Timothy Grass (*Phleum pratense*): 6 manufacturers
         Short Ragweed (*Ambrosia artemisiifolia*): 6 manufacturers
         Honey Bee Venom (*Apis mellifera*): 2 manufacturers
         Wasp Venom Protein (*Polistes spp*): 2 manufacturers
         Yellow Hornet Venom Protein (*Dolichovespula arenaria*): 2 manufacturers
         Yellow Jacket Venom Protein (*Vespula spp*): 2 manufacturers
         Mixed Vespid Venom Protein (mixed yellow jacket, yellow hornet, and white-faced hornet): 2 manufacturers
     *Injectable allergen extracts, nonstandardized* (<https://www.fda.gov/BiologicsBloodVaccines/Allergenics/ucm391517.htm>)
         Six companies are licensed to manufacture and distribute such extracts
     *Allergen extracts: sublingual tablets for AIT* (<https://www.fda.gov/BiologicsBloodVaccines/Allergenics/ucm391505.htm>)
         GRASTEK Merck Sharp & Dohme Corp: Timothy grass pollen extract
         ORALAIR Stallergenes S.A.L.: mix of 5 grass species
         ODACTRA Merck Sharp & Dohme Corp: House dust mite (*Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*) allergen extract
         RAGWITEK Merck Sharp & Dohme Corp: Short ragweed pollen extract
  **[Germany]{.ul}** (<https://www.pei.de/DE/arzneimittel/allergene/allergene-node.html>)
     *Allergen extracts for skin prick testing:* <https://www.pei.de/DE/arzneimittel/allergene/test-allergene/pricktest/pricktest-node.html>
         • Grass-, corn-, weed pollen
         • Tree pollen
         • Food
         • Molds and yeast
         • House dust mites/storage mites
         • Animal dander/hair
         • Venoms
         • Latex
     *Allergen extracts for provocation testing:*<https://www.pei.de/DE/arzneimittel/allergene/test-allergene/provokationstest/provokationstest-node.html>
         • Grass-, corn-, weed pollen
         • Tree pollen
         • Food
         • Molds and yeast
         • House dust mites/storage mites
         • Animal dander/hair
     *For AIT:*
     *For subcutaneous AIT:* <https://www.pei.de/DE/arzneimittel/allergene/therapie-allergene/subkutan/subkutane-therapie-node.html;jsessionid=FD6BE393DB5711476E2BC4D3FDCBF8C4.1_cid319>
         Grass-, corn-, and weed pollen: <https://www.pei.de/DE/arzneimittel/allergene/therapie-allergene/subkutan/graeser/graeser-getreide-kraeuter-pollen-node.html>
         25 products
         Tree pollen: <https://www.pei.de/DE/arzneimittel/allergene/therapie-allergene/subkutan/baumpollen/baumpollen-node.html>
         44 products
         House dust mites: <https://www.pei.de/DE/arzneimittel/allergene/therapie-allergene/subkutan/hausstaubmilben/hausstaubmilben-node.html>
         28 products
         Venoms: <https://www.pei.de/DE/arzneimittel/allergene/therapie-allergene/subkutan/insektengifte/insektengifte-node.html>
         18 products
     *Sublingual AIT:*
         Grass-, corn-, weed pollen: <https://www.pei.de/DE/arzneimittel/allergene/therapie-allergene/sublingual/graeser/graeser-getreide-kraeuter-pollen-node.html>
         27 products
         Tree pollen: <https://www.pei.de/DE/arzneimittel/allergene/therapie-allergene/sublingual/baumpollen/baumpollen-node.html>
         4 products
         House dust mites: <https://www.pei.de/DE/arzneimittel/allergene/therapie-allergene/sublingual/hausstaubmilben/hausstaubmilben-node.html>
         3 products
  [**Russia**]{.ul}
     *For in vivo diagnostic purposes:*
         Water-salt allergen extracts produced by AO "Biomed" Mechnikov
         Water-salt allergen extracts produced by NPO Microgen
     *For AIT:*
         Water-salt allergen extracts produced by AO "Biomed" Mechnikov and by NPO Microgen
         Subcutaneus AIT "Phostal," "Alustal" (Stallergenes, France): tree pollen, grass pollen, HDM
         Sublingual AIT "Staloral" (Stallergenes, France): HDM, birch pollen
         Sublingual tablet "Oralair" (Stallergenes, France): grass pollen
         Sublingual AIT by allergoids (Lopharma, Italy): HDM, grass pollen
  [**Asia**]{.ul}
     **Japan**
         In Japan allergen products are considered as biomedicines
     *For in vivo diagnostic purposes:*
         Extracts from Tori Pharmaceutical Co. <https://www.torii.co.jp/en/>
         Allergen extract for Scratch test: HDM "TORII" 100,000 JAU/mL,
         Dermatophagoides farinae extract 10,000 AU/mL,
         Dermatophagoides pteronyssinus extract 10,000 AU/mL.
         Allergen Scratch Extract Positive control "TORII" Histamine dihydrochloride
     *For AIT:*
         Miticure House Dust Mite Sublingual Tablets 3,300 JAU Miticure House Dust Mite Sublingual Tablets 10,000 JAU (Torii Pharmaceutical Co., Ltd.) (Dermatophagoides farinae extract, Dermatophagoides pteronyssinus extract)
         Actair 100 IR Sublingual Tablets-HDM Actair 300 IR Sublingual Tablets-HDM (Shionogi & Co., Ltd.) Dermatophagoides farinae extract bulk powder, Dermatophagoides pteronyssinus extract bulk powder.
         Allergen extract for subcutaneous injection-HDM "TORII" 100,000 JAU/mL
         Allergen extract for subcutaneous injection-HDM "TORII" 10,000 JAU/mL (Torii Pharmaceutical Co., Ltd.)
         Cedartolen Sublingual Drop-Japanese Cedar Polllen 200 JAU/mL bottle
         Cedartolen Sublingual Drop-Japanese Cedar Polllen 2,000 JAU/mL bottle
         Standardized Japanese cedar pollen extract original solution 10,000 JAU/mL
  **Taiwan**
         Allergen extracts available from Allermed (USA), now merged by Greer Co. (USA).
  **China**
         Allergen extracts available from:
         ALK (Horsholm, DenmarK), Stallergenes Greer. Co. (USA), WolwoPharma. Co. (China) (<http://www.wolwobiotech.com/>)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AIT, Alergen-specific immunotherapy; HDM, house dust mite.
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AIT

:   Allergen-specific immunotherapy

BLA

:   Biologics license application

EU

:   European Union

GCP

:   Good clinical practice

GMP

:   Good manufacturing practice
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###### Advantages and disadvantages of methods for the quality control of allergen extracts

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Measurement of protein contents (quantitative by nitrogen determination, qualitative by SDS-PAGE)
       Advantage
         Measures amount/quality of proteins, applicable to denatured allergen extracts
       Disadvantage
         Does not identify allergen molecules and does not discriminate between allergenic and nonallergenic components in extracts; does not inform about immunogenicity
  Determination of IgE reactivity and allergenic activity (IgE reactivity, basophil activation, skin testing)
       Advantage
         Measures IgE reactivity and allergenic activity of an extract
       Disadvantage
         Does not identify allergen molecules and does not discriminate between allergenic and nonallergenic components in extracts; does not inform about immunogenicity
  Determination of IgE reactivity and allergenic activity (IgE reactivity, basophil activation, skin testing)
       Advantage
         Measures IgE reactivity and allergenic activity of an extract
       Disadvantage
         Does not discriminate between allergens, shows IgE reactivity and allergenic reactivity only for 1 standard, only limiting amounts of the standard available; results may vary depending on the standard and do not reflect the situation in individual patients at different times, does not inform about immunogenicity, not applicable to denatured allergen extracts
  Mass spectrometry
       Advantage
         Identifies allergen-derived materials according to characteristic mass
       Disadvantage
         Not suited for exact quantification, cannot discriminate between complete IgE-reactive allergens and nonallergenic allergen-derived materials such as allergen fragments/peptides, does not inform about immunogenicity
  Circular dichroism, size exclusion
       Advantage
         Determine the fold of proteins and their aggregation behavior
       Disadvantage
         Usually only suitable for purified proteins, do no inform about IgE reactivity and allergenic activity, do not provide quantitative information, do not inform about immunogenicity, and not applicable to denatured allergen extracts
  ELISA for quantification of allergens
       Advantage
         Allows quantifying of individual allergens
       Disadvantage
         Not available for each of the allergens, difficulty to discriminate between allergen isoforms and allergen-derived materials, does not necessarily measure IgE reactivity and allergenic activity, does not inform about immunogenicity, not applicable to denatured allergen extracts
  Qualitative allergen detection (eg, immunoblotting)
       Advantage
         Visualizes the presence of allergens in an extract with specific antibody probes
       Disadvantage
         Does not allow a quantification of allergens, does not identify nonallergenic materials/contaminants, does not inform about allergenic activity or immunogenicity
  Immunization
       Advantage
         Informs about the immunogenicity of allergen extracts and denatured allergen extracts regarding the induction of allergen-specific IgE and IgG antibodies on immunization of animals, applicable also for denatured/modified allergen extracts
       Disadvantage
         Does not allow quantifying individual allergens, does not identify allergens, does not inform about IgE reactivity and allergenic activity of the extract; results obtained for certain animals (eg, inbred mouse strains) do not necessarily reflect immunization of humans, may induce cross-reactive antibodies reacting also with other allergen sources
  Safety and stability assays (chemical, biological)
       Measurement of endotoxins and foreign nucleic acids: mandatory for *in vivo* use in humans, useful to determine contents of endotoxins, foreign nucleic acids, and immunomodulatory substances
       Sterility tests: mandatory for *in vivo* use in humans, prevent administration of potentially infectious materials to humans
       Toxicity tests: *in vivo* and *in vitro* tests (single-dose, repeated-dose, genotoxcitiy studies) to determine toxic effects, mandatory for *in vivo* use in humans, prevent administration of potentially toxic and mutagenic materials to humans
       Stability tests: tests measuring the stability of the active ingredients in an extract (allergens, modified allergens) to ensure the desired activity, mandatory for *in vivo* use in humans, useful to prevent the administration of material with reduced or lost activity
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*ELISA*, Enzyme-linked immunosorbent assay; *SDS-PAGE*, sodium dodecyl sulfate polyacrylamide gel electrophoresis.

###### Advantages and disadvantages of natural allergen extracts and recombinant/synthetic allergen molecules

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Natural allergen extracts
      Advantages
          • Preparation without extensive purification steps
          • Contain several allergens of the allergen source
          • Often reflect the allergen contents of the natural allergen sources
          • Are already on the market with old authorizations
          • Known to allergologists as traditional products
      Disadvantages/limitations
          • May contain nonallergenic components with different properties
          • May be contaminated with allergens from other sources
          • May present variable contents and ratios of allergens
          • May present batch-to-batch variations due to manufacturing procedures and raw materials
          • May be unstable and degrade
          • Contents cannot be fully influenced by the manufacturer but are determined by the raw material
          • Do not provide molecular information when used for diagnosis
          • May cause allergic reactions on administration
          • May not fulfill modern regulatory requirements for medicinal products
          • May contain infectious materials
  Recombinant/synthetic allergen molecules
      Advantages
          • Pure proteins/peptides of defined properties and quality
          • Manufactured according to good manufacturing practice
          • Can be produced in defined amounts and concentrations in reproducible manner
          • Fulfill regulatory requirements for medicinal products, modern drugs, and vaccines
          • Allergenic, immunogenic, and tolerogenic properties are predefined
          • Allow specific targeting of immune mechanisms (eg, IgG induction, tolerance induction)
          • Allow patient-tailored treatment
          • Multiple advantages when used for diagnosis (ie, identification of culprit allergen molecules, revealing cross-reactivity, providing molecular profiles)
          • Provide detailed diagnostic test information
          • Production is independent of allergen raw materials
          • Can be produced at costs comparable to natural allergen extracts
          • Biologically safe due to GMP production
      Possible disadvantages
          • Require knowhow
          • Require modern recombinant or synthetic production process
          • Require new market authorization and clinical studies
          • Need to produce different components
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

*GMP*, Good manufacturing practice.

###### Clinical trials with recombinant allergens, recombinant allergen derivatives and synthetic allergen-derived peptides

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Molecules/approximate timeframe                                                Description of the vaccine                                                                                                                                                             Study design and clinical trial number                                               References
  ------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ---------------------------
  **AllervaxCAT, 1996-1999**                                                     Two Fel d 1-derived peptides of 27 amino acids                                                                                                                                         SCIT, DBPC                                                                           [@R117], [@R118], [@R119]

  Bet v 1 trimer, Bet v 1 fragments, 2000-2001                                   Hypoallergenic recombinant derivatives of Bet v 1                                                                                                                                      Phase II, SCIT/DBPC                                                                  [@R24]

  rPhl p 1, rPhlp 2, rPhlp 5a + b, rPhl p 6, 2002-2013                           Recombinant grass pollen allergen cocktail                                                                                                                                             Phase II, SCIT/DBPC NCT00671268, NCT00309036                                         [@R25]

  Folding variant of Bet v 1, 2002-2013                                          Hypoallergenic recombinant folding variant of the major birch pollen allergen (rBet v 1-FV)                                                                                            Phase III, SCIT/DBPC NCT00266526, NCT00554983, NCT00841516                           [@R28], [@R120]

  rBet v 1, 2002-2008                                                            Comparison of rBet v 1 with nBet v 1 and birch pollen extract for SCIT in birch pollen allergic patients                                                                               Phase II, SCIT/DBPC NCT00410930                                                      [@R26]

  rBet v 1 tablets, 2006-2013                                                    r Bet v1 administered as sublingual tablets in birch pollen allergic subjects                                                                                                          Phase II, SLIT, DBPC NCT00901914 NCT00396149, NCT00889460                            [@R121]

  ILIT with MAT-Fel d 1, 2008-2010                                               Intralymphatic immunotherapy for cat allergy                                                                                                                                           Phase I, NCT00718679                                                                 [@R122]

  Ara h 1, Ara h 2, and Ara h 3, 2009-2013                                       Rectal application of *E. coli*-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3                                                                       Phase I, safety study NCT00850668                                                    [@R123]

  Fcγ1-Fel d1 fusion protein, 2011-2014                                          Intradermal, human Fcγ1-Fel d 1 fusion protein                                                                                                                                         Safety study, NCT01292070                                                            [@R124]

  BM 32, 2012-2017                                                               Hypoallergenic recombinant vaccine for immunotherapy of grass pollen allergy consisting of derivatives of the 4 major grass pollen allergens, phl p 1, Phl p 2, Phl p 5, and Phl p 6   Phase IIa and 2 phase IIb studies, SCIT/DBPC NCT01350635, NCT01538979, NCT02643641   [@R30], [@R31]

  ToleroMune Cat, 2012-2016                                                      Fel d 1-derived synthetic peptides for induction of tolerance in cat allergic patients                                                                                                 Phase III, intradermal/DBPC NCT01620762                                              [@R125], [@R126]

  AllerT, 2012-2015                                                              Bet v 1-derived contiguous overlapping peptides                                                                                                                                        Phase IIb, SCIT/DBPC NCT01720251, NCT02143583, NCT02271009\                          [@R29], [@R127], [@R128]
                                                                                                                                                                                                                                                                        Long-term follow-up of a phase IIb study AN004T                                      

  Sublingual immunotherapy of birch pollen-associated apple allergy, 2012-2016   Recombinant Mal d 1                                                                                                                                                                    Single-center, double-blind, placebo-controlled explorative study NCT01449786        [@R129]

  FAST-Fish, 2013-2015                                                           SCIT for fish allergy based on the subcutaneous application of mutated parvalbumin (rCyp p 1)                                                                                          Phase IIa, NCT02017626                                                               [@R109]

  ToleroMune Grass, 2014-2016                                                    Short peptides from grass pollen allergens                                                                                                                                             Phase IIb/III started intradermal/DBPC NCT02795273, NCT02161107                      

  ToleroMune HDM, 2014-2016                                                      Short peptides derived from house dust mite allergens                                                                                                                                  Phase II, intradermal/DBPC NCT02150343                                               

  ToleroMune Ragweed, 2014-2016                                                  Short peptides from Amb a 1                                                                                                                                                            Phase II, NCT02061709, NCT02396680                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*DBPC*, Double-blind, placebo-controlled; *HDM*, house dust mite; *SCIT*, subcutaneous immunotherapy.
